Across TCGA pan-cancer cohorts, IGLV2-23 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated IGLV2-23 data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher IGLV2-23 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated IGLV2-23 expression acts as an unfavorable survival marker.

BLCA, UCEC, and SKCM are the cancer types where IGLV2-23 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	All	0.139	0.626	.010	18	view →
UCEC	OS	Median	III,IV	0.061	0.588	.018	12	view →
SKCM	DFS	Median	All	0.015	0.758	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: IGLV2-23 tumor-vs-normal RNA expression · all IGLV2-23 data types